Agomab Therapeutics reported a successful IPO raising $208 million, boosting its cash reserves to €116.5 million as of end-2025, expected to fund operations into mid-2029. The company is progressing clinical trials for two key drugs: ontunisertib for fibrostenosing Crohn's disease and AGMB-447 for idiopathic pulmonary fibrosis, with Phase 2 studies planned to start in the second half of 2026. Positive regulatory feedback and upcoming data readouts later this year highlight Agomab's advancing pipeline in fibro-inflammatory diseases. This financial strength and clinical momentum position Agomab well for future growth and development.
Barclays increased its price target for Hudbay Minerals to $32 from $30, citing strong growth prospects in copper mining. Despite a recent nearly 30% stock pullback due to market sentiment, Hudbay maintains a solid financial position with near-zero n...
Morgan Stanley reported strong Q2 2026 results, with earnings per share of $3.46 surpassing estimates of $2.89 and revenue of $21.35 billion beating forecasts of $19.67 billion. This marks significant year-over-year growth from $16.79 billion, driven...
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
